These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

534 related items for PubMed ID: 16344320

  • 1. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.
    Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA.
    J Clin Oncol; 2006 Jan 20; 24(3):379-85. PubMed ID: 16344320
    [Abstract] [Full Text] [Related]

  • 2. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
    Goel A, Grossbard ML, Malamud S, Homel P, Dietrich M, Rodriguez T, Mirzoyev T, Kozuch P.
    Anticancer Drugs; 2007 Mar 20; 18(3):263-71. PubMed ID: 17264757
    [Abstract] [Full Text] [Related]

  • 3. A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
    Davis EJ, Griffith KA, Kim EJ, Ruch JM, McDonnell KJ, Zalupski MM.
    Am J Clin Oncol; 2018 Feb 20; 41(2):128-132. PubMed ID: 26535993
    [Abstract] [Full Text] [Related]

  • 4. A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer.
    El-Rayes BF, Zalupski MM, Shields AF, Ferris AM, Vaishampayan U, Heilbrun LK, Venkatramanamoorthy R, Adsay V, Philip PA.
    Invest New Drugs; 2005 Dec 20; 23(6):583-90. PubMed ID: 16034525
    [Abstract] [Full Text] [Related]

  • 5. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.
    Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R.
    J Clin Oncol; 2006 Aug 20; 24(24):3946-52. PubMed ID: 16921047
    [Abstract] [Full Text] [Related]

  • 6. Phase II study of combination chemotherapy with gemcitabine and cisplatin for patients with metastatic pancreatic cancer.
    Ueno H, Okusaka T, Ikeda M, Morizane C, Ogura T, Hagihara A, Tanaka T.
    Jpn J Clin Oncol; 2007 Jul 20; 37(7):515-20. PubMed ID: 17675286
    [Abstract] [Full Text] [Related]

  • 7. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.
    Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, Cigolari S, Testa A, Maiello E, Lopez M.
    Cancer; 2002 Feb 15; 94(4):902-10. PubMed ID: 11920457
    [Abstract] [Full Text] [Related]

  • 8. Fixed dose-rate infusion of gemcitabine in combination with cisplatin and UFT in advanced carcinoma of the pancreas.
    Feliu J, Sáenz JG, Jaráiz AR, Castañón C, Cruz M, Fonseca E, Lomas M, Castro J, Jara C, Casado E, León A, Barón MG.
    Cancer Chemother Pharmacol; 2006 Oct 15; 58(4):419-26. PubMed ID: 16404636
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin?
    Stemmler J, Stieber P, Szymala AM, Schalhorn A, Schermuly MM, Wilkowski R, Helmberger T, Lamerz R, Stoffregen C, Niebler K, Garbrecht M, Heinemann V.
    Onkologie; 2003 Oct 15; 26(5):462-7. PubMed ID: 14605463
    [Abstract] [Full Text] [Related]

  • 11. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
    Kulke MH, Tempero MA, Niedzwiecki D, Hollis DR, Kindler HL, Cusnir M, Enzinger PC, Gorsch SM, Goldberg RM, Mayer RJ.
    J Clin Oncol; 2009 Nov 20; 27(33):5506-12. PubMed ID: 19858396
    [Abstract] [Full Text] [Related]

  • 12. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.
    Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J.
    J Clin Oncol; 2003 Sep 15; 21(18):3402-8. PubMed ID: 12885837
    [Abstract] [Full Text] [Related]

  • 13. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
    Ko AH, Truong TG, Kantoff E, Jones KA, Dito E, Ong A, Tempero MA.
    Cancer Chemother Pharmacol; 2012 Dec 15; 70(6):875-81. PubMed ID: 23053263
    [Abstract] [Full Text] [Related]

  • 14. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.
    Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E, Di Carlo V.
    Lancet Oncol; 2005 Jun 15; 6(6):369-76. PubMed ID: 15925814
    [Abstract] [Full Text] [Related]

  • 15. Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer.
    Lee J, Park JO, Kim WS, Lee SI, Song SY, Lim DH, Choi SH, Heo JS, Lee KT, Lee JK, Kim K, Jung CW, Im YH, Lee MH, Kang WK, Park K.
    Oncology; 2004 Jun 15; 66(1):32-7. PubMed ID: 15031596
    [Abstract] [Full Text] [Related]

  • 16. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
    Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O'Dwyer P, Haller D, Catalano P, Cella D, Benson AB.
    J Clin Oncol; 2009 Aug 10; 27(23):3778-85. PubMed ID: 19581537
    [Abstract] [Full Text] [Related]

  • 17. Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas.
    Feliu J, Mel R, Borrega P, López Gómez L, Escudero P, Dorta J, Castro J, Vázquez-Estévez SE, Bolaños M, Espinosa E, González Barón M, Oncopaz cooperative group, Spain.
    Ann Oncol; 2002 Nov 10; 13(11):1756-62. PubMed ID: 12419748
    [Abstract] [Full Text] [Related]

  • 18. Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma.
    Reni M, Passoni P, Panucci MG, Nicoletti R, Galli L, Balzano G, Zerbi A, Di Carlo V, Villa E.
    J Clin Oncol; 2001 May 15; 19(10):2679-86. PubMed ID: 11352960
    [Abstract] [Full Text] [Related]

  • 19. Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer.
    El-Rayes BF, Zalupski MM, Shields AF, Vaishampayan U, Heilbrun LK, Jain V, Adsay V, Day J, Philip PA.
    J Clin Oncol; 2003 Aug 01; 21(15):2920-5. PubMed ID: 12885810
    [Abstract] [Full Text] [Related]

  • 20. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
    Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA.
    Invest New Drugs; 2008 Oct 01; 26(5):463-71. PubMed ID: 18379729
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.